All In Biotech

Drug Trial Radar · NCT00835770

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Dec 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,736 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,736

Actual

Start

Feb 3, 2009

Primary completion

Nov 8, 2019

Study completion Nov 8, 2019

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Feb 4, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 19 years, up to 58 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

  • dimethyl fumarateDrug

    BG00012 capsules

  • PlaceboDrug

    Capsules taken to maintain the blind in the 240 mg BID treatment group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs)Time frame: Day 1 up to Week 561

Locations

246 sites in 34 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • research Site

    Mesa, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Loma Linda, California

  • Research Site

    Boulder, Colorado

  • Research Site

    Fort Collins, Colorado

  • Research Site

    North Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Maitland, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Naples, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Evanston, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Kansas City, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Chesterfield, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Albany, New York

  • Research Site

    Amherst, New York

  • Research Site

    Buffalo, New York

  • Research Site

    Patchogue, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Bellevue, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Dayton, Ohio

  • Research Site

    Medford, Oregon

  • Research Site

    Portland, Oregon

Showing 40 of 246 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.